ReviewNature reviews. Microbiology2022
Anti-tuberculosis treatment strategies and drug development: challenges and priorities.
Review in Nature reviews. Microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
230 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment shortening and relapse control in drug-susceptible pulmonary tuberculosis: a network meta-analysis of randomized trials.Frontiers in cellular and infection microbiology · 2026Pooled it
- Current update on surgical management for spinal tuberculosis: a scientific mapping of worldwide publications.Frontiers in surgery · 2024Pooled it
- Design, Synthesis, Antimycobacterial Evaluation, and In Silico Investigation of Benzisothiazole-Based Hydrazide Derivatives as Potential Anti-Tuberculosis Agents.Chemical biology & drug design · 2026Article
- Exploiting Multicomponent Reactions to Drive the Development of Novel Antitubercular Agents: An Overview.ChemMedChem · 2026Review
- What is new in tuberculosis?Clinical medicine (London, England) · 2026Review
- Sorting nexin 5 deficiency impairs MHC class II antigen presentation and inflammatory responses during tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Synergism in drug combination of new tuberculosis antibiotics for drug-resistantMicrobiology spectrum · 2026Article
- A Trehalose-Based Phenotypic Screen Identifies Candidate Inhibitors ofAntibiotics (Basel, Switzerland) · 2026Article
- Fast-growing intracellular Mycobacterium tuberculosis populations evade antibiotic treatment.Nature communications · 2026Article
- AssessingbioRxiv : the preprint server for biology · 2026Article
- Enriching Bacteria-Specific RNA From Host Samples Before NGS With Transcript-Capture.Bio-protocol · 2026Article
- Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors againstACS infectious diseases · 2026Article
- The Sialomucin CD43 Drives Tuberculosis Immunopathology Across Different Host Genetic Backgrounds.Inflammation · 2026Article
- Peptide Mimetic Platform for Activity Profiling of Mycobacterial l,d-Transpeptidases.Biochemistry · 2026Article
- Growth arrest of Mycobacterium tuberculosis in acidic environments enhances their survival of antibiotic treatment.PLoS biology · 2026Article
- Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.Biomedicines · 2026Review
- Bacterial L-forms: Key Mechanisms of Drug Resistance, Disease Recurrence, and Immune Evasion.Indian journal of microbiology · 2026Review
- Antimicrobial Armageddon: The Professional Guide to Conquering Antibiotic Resistance.Probiotics and antimicrobial proteins · 2026Article
- SPIC-dependent erythrophagocytic macrophages drive granuloma formation and pathogen persistence during intracellular bacterial infection.bioRxiv : the preprint server for biology · 2026Article
- Combination strategies targeting multiple ETC subunits as a rational approach for drug-resistant TB therapy.Archives of microbiology · 2026Review
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite two decades of intensified research to understand and cure tuberculosis disease, biological uncertainties remain and hamper progress. However, owing to collaborative initiatives including academia, the pharmaceutical industry and non-for-profit organizations, the drug candidate pipeline is promising. This exceptional success comes with the inherent challenge of prioritizing multidrug regimens for clinical trials and revamping trial designs to accelerate regimen development and capitalize on drug discovery breakthroughs. Most wanted are markers of progression from latent infection to active pulmonary disease, markers of drug response and predictors of relapse, in vitro tools to uncover synergies that translate clinically and animal models to reliably assess the treatment shortening potential of new regimens. In this Review, we highlight the benefits and challenges of 'one-size-fits-all' regimens and treatment duration versus individualized therapy based on disease severity and host and pathogen characteristics, considering scientific and operational perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.